Who is on it, and how far along Every drug ChEMBL records acting on PIK3CA, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Phase 34 Gedatolisib Gedatolisib SponsorCelcuity ModalitySmall molecule ActionInhibitor Open trials5 Dactolisib Dactolisib SponsorresTORbio ModalitySmall molecule ActionInhibitor Open trials2 Taselisib Taselisib SponsorRoche ModalitySmall molecule ActionInhibitor Open trials2 Buparlisib Buparlisib SponsorAdlai Nortye ModalitySmall molecule ActionInhibitor Open trials0 Phase 216 Omipalisib Omipalisib SponsorGSK ModalitySmall molecule ActionInhibitor Open trials9 Paxalisib Paxalisib SponsorSovargen ModalitySmall molecule ActionInhibitor Open trials8 Samotolisib Samotolisib SponsorEli Lilly ModalitySmall molecule ActionInhibitor Open trials1 Apitolisib Apitolisib SponsorRoche ModalitySmall molecule ActionInhibitor Open trials0 AZD-6482 AZD-6482 SponsorNot known ModalitySmall molecule ActionInhibitor Open trials0 BGT-226 free base BGT-226 free base SponsorNovartis Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials0 Izorlisib Izorlisib SponsorChugai Pharmaceutical ModalitySmall molecule ActionInhibitor Open trials0 Panulisib Panulisib SponsorPiramal Group ModalitySmall molecule ActionInhibitor Open trials0 PF-04691502 PF-04691502 SponsorPfizer ModalitySmall molecule ActionInhibitor Open trials0 Pictilisib Pictilisib SponsorRoche ModalitySmall molecule ActionInhibitor Open trials0 Pilaralisib Pilaralisib SponsorSanofi ModalitySmall molecule ActionInhibitor Open trials0 Recilisib Recilisib SponsorNot known ModalitySmall molecule ActionInhibitor Open trials0 SF-1126 SF-1126 SponsorSignalRX Pharmaceuticals, Inc. ModalitySmall molecule ActionInhibitor Open trials0 Sonolisib Sonolisib SponsorCascadian Therapeutics ModalitySmall molecule ActionInhibitor Open trials0 Voxtalisib Voxtalisib SponsorSanofi ModalitySmall molecule ActionInhibitor Open trials0 ZSTK-474 ZSTK-474 SponsorZenyaku Kogyo Co., Ltd. ModalitySmall molecule ActionInhibitor Open trials0 Phase 16 DS-7423 DS-7423 SponsorDaiichi Sankyo ModalityOther ActionInhibitor Open trials0 GSK-1059615 GSK-1059615 SponsorGSK ModalitySmall molecule ActionInhibitor Open trials0 Puquitinib Puquitinib SponsorNot known ModalitySmall molecule ActionInhibitor Open trials0 PWT-33587 PWT-33587 SponsorNot known ModalityOther ActionInhibitor Open trials0 VS-5584 VS-5584 SponsorVerastem ModalitySmall molecule ActionInhibitor Open trials0 WX-037 WX-037 SponsorHeidelberg Pharma AG ModalityOther ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: PI3-kinase class I inhibitor. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 25 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT) Paxalisib Phase 2 Recruiting Sabine Mueller, MD, PhD Mar 3, 2026 5G-PEARL: Paxalisib in Malignant Brain Tumours Paxalisib Phase 1 / Phase 2 Recruiting Institute of Cancer Research, United Kingdom Feb 5, 2026 Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME) Paxalisib Phase 1 / Phase 2 Recruiting Sovargen Dec 17, 2025 Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) Gedatolisib Phase 3 Recruiting Celcuity Inc Jan 3, 2025 Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer Omipalisib Phase 3 Recruiting ECOG-ACRIN Cancer Research Group Jun 26, 2024 Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Paxalisib Phase 1 / Phase 2 Recruiting Australian & New Zealand Children's Haematology/Oncology Group Jan 17, 2024 Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer Gedatolisib Phase 1 / Phase 2 Recruiting Celcuity Inc Jan 5, 2024 Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) Gedatolisib Phase 3 Active, not recruiting Celcuity Inc Aug 16, 2022 Combination Therapy for the Treatment of Diffuse Midline Gliomas Paxalisib Phase 2 Recruiting University of California, San Francisco Aug 18, 2021 Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL Paxalisib Phase 2 Recruiting Lakshmi Nayak, MD May 28, 2021 A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults Dactolisib Phase 2 Active, not recruiting Restorbio Inc. Oct 14, 2020 Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) Taselisib Phase 2 Active, not recruiting National Cancer Institute (NCI) Jun 19, 2020 Genetic Testing in Guiding Treatment for Patients With Brain Metastases Paxalisib Phase 2 Active, not recruiting Alliance for Clinical Trials in Oncology Jun 21, 2019 A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma Paxalisib Phase 2 / Phase 3 Recruiting Global Coalition for Adaptive Research May 31, 2019 Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Gedatolisib Phase 1 / Phase 2 Active, not recruiting Kari Wisinski Apr 11, 2019 RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer Gedatolisib Phase 2 Recruiting Dana-Farber Cancer Institute Sep 18, 2018 Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly Dactolisib Phase 2 Active, not recruiting Restorbio Inc. Dec 14, 2017 Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Omipalisib Phase 2 Active, not recruiting National Cancer Institute (NCI) Jun 19, 2017 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Samotolisib Phase 2 Active, not recruiting National Cancer Institute (NCI) May 16, 2017 Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer Omipalisib Phase 2 Active, not recruiting National Cancer Institute (NCI) Dec 30, 2015 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Omipalisib, Taselisib Phase 2 Active, not recruiting National Cancer Institute (NCI) Jun 8, 2015 Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer Omipalisib Phase 2 Active, not recruiting National Cancer Institute (NCI) Jun 2, 2014 Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors Omipalisib Phase 1 / Phase 2 Active, not recruiting National Cancer Institute (NCI) Mar 6, 2014 Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases Omipalisib Phase 1 Active, not recruiting National Cancer Institute (NCI) Dec 19, 2013 Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma Omipalisib Phase 1 / Phase 2 Active, not recruiting National Cancer Institute (NCI) Nov 21, 2013
Show all 25Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3559703 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. ChEMBL and Open Targets